FDA Grants Market Clearance To Aerocrine Inc.’s NIOX MINO(R): A New Hand-Held Device To Measure Airway Inflammation In Asthma

NIOX MINO(R) Set to Dramatically Improve Airway Inflammatory Disease Management through Personalized Inflammation Control. Aerocrine, Inc. (STO:AEROB) announced that NIOX MINO, a hand-held point-of-care device for the measurement of airway inflammation, has been 510(k) cleared by the U.S. Food and Drug Administration (FDA). Physicians in the U.S.

More: continued here

Filed under: Respiratory on March 15th, 2008